Sign in

You're signed outSign in or to get full access.

Joanne Wunsch

Managing Director at Citi

Joanne Wuensch is a Managing Director at Citi Research, specializing in Medical Technology and Hospital Supplies within the Healthcare sector. She covers specific companies including Abbott Laboratories (ABT), Johnson & Johnson (JNJ), Medtronic (MDT), Boston Scientific (BSX), Bausch + Lomb (BLCO), Edwards Lifesciences, and Intuitive Surgical, with a strong performance track record featuring a 59% success rate across 484 ratings and an average return of 5.20% per rating, ranking her in the top 15% of Wall Street analysts on TipRanks. Wuensch joined Citi in January 2020 after 18 years at BMO Capital Markets focusing on MedTech sectors like cardiology, diabetes, orthopaedics, ophthalmology, and respiratory, with prior roles at ABN Amro, ING Barings, UBS Securities, and JP Morgan. She holds an MPA from New York University in public finance including hospital finance and a BA in psychology from the University of Delaware.

Joanne Wunsch's questions to ABBOTT LABORATORIES (ABT) leadership

Question · Q4 2025

Joanne Wunsch inquired about the outlook for Abbott's Established Pharmaceutical Products (EPD) business, considering potential macro landscape complications, and sought insights into the growth drivers and upcoming catalysts for the structural heart portfolio.

Answer

Chairman and CEO Robert Ford expressed confidence in the EPD team's resilience to navigate macro challenges, expecting sustained 7-9% growth driven by a differentiated portfolio and the introduction of biosimilars. For structural heart, Mr. Ford highlighted heavy investments leading to a best-in-class portfolio. He cited upcoming growth catalysts including new products (Navitor, TriClip, Amulet), double-digit growth in MitraClip due to guideline changes, TriClip approval in Japan, and bolt-on M&A (Lower Lab for AI-powered imaging). He also detailed a strong pipeline with next-gen Amulet (early 2027 launch), an ID trial for balloon TAVR (H2 2026), and a femoral transseptal mitral valve replacement program.

Ask follow-up questions

Fintool

Fintool can predict ABBOTT LABORATORIES logo ABT's earnings beat/miss a week before the call

News for Covered Companies

Abbott CEO Ford Buys $2M of Stock After Earnings Selloff—A Classic Insider Signal

Abbott CEO Ford Buys $2M of Stock After Earnings Selloff—A Classic Insider Signal

ABTJan 26
Abbott Plunges 9% on $340M Revenue Miss as Nutrition Business Hits Breaking Point

Abbott Plunges 9% on $340M Revenue Miss as Nutrition Business Hits Breaking Point

ABTJan 22